

10088677-053100  
 3005 RECEIVED PTO 21 MAR 2002

FORM PTO-1390 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER <b>620-190</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES          DESIGNATED/ELECTED OFFICE (DO/EO/US)          CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>10/088677</b> Unassigned
INTERNATIONAL APPLICATION NO. <b>PCT/GB00/03601</b>	INTERNATIONAL FILING DATE <b>20 September 2000</b>	PRIORITY DATE CLAIMED <b>21 September 1999</b>


TITLE OF INVENTION <b>USE OF REPLICATION-DEFICIENT ADENOVIRAL VECTOR TO BOOST CD8+T CELL IMMUNE RESPONSE TO ANTIGEN</b>		
APPLICANT(S) FOR DO/EO/US <b>SCHNEIDER et al</b>		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
- ☒ The U.S. has been elected by the expiration of 19 months from the priority date (Article 31).
- A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
  - ☐ is attached hereto (required only if not communicated by the International Bureau).
  - ☒ has been communicated by the International Bureau.
  - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - ☐ is attached hereto.
  - ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - ☐ are attached hereto (required only if not communicated by the International Bureau).
  - ☐ have been communicated by the International Bureau.
  - ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
  - ☐ have not been made and will not be made.
- ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 To 20 below concern document(s) or information included:**

- ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
- ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
- ☒ A FIRST preliminary amendment.
- ☐ A SECOND or SUBSEQUENT preliminary amendment.
- ☐ A substitute specification.
- ☐ A change of power of attorney and/or address letter.
- ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
- ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
- ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
- ☐ Other items or information.

U.S. APPLICATION NO. <u>10088677</u> Use design		INTERNATIONAL APPLICATION NO. <b>PCT/GB00/03601</b>		ATTORNEY'S DOCKET NUMBER <b>620-190</b>													
21. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b> PTO USE ONLY													
<b>BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):</b> -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....\$1040.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$890.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO .....\$740.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00				<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:10%;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></td> <td style="width:40%;">\$</td> <td style="width:10%;">890.00</td> <td style="width:10%;"></td> <td style="width:10%;"></td> <td style="width:10%;"></td> </tr> <tr> <td>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).</td> <td>\$</td> <td>130.00</td> <td></td> <td></td> <td></td> </tr> </table>		<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>	\$	890.00				Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).	\$	130.00			
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>	\$	890.00															
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).	\$	130.00															
<b>CLAIMS</b>	<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>														
Total Claims	8	-20 =	0	X	\$18.00												
Independent Claims	2	-3 =	0	X	\$84.00												
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)					\$280.00												
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	<b>1020.00</b>												
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.																	
<b>SUBTOTAL =</b>				\$	<b>1020.00</b>												
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).																	
<b>TOTAL NATIONAL FEE =</b>				\$	<b>1020.00</b>												
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). <b>\$40.00</b> per property																	
<b>Fee for Petition to Revive Unintentionally Abandoned Application (\$1280.00 - Small Entity = \$640.00)</b>				\$	<b>0.00</b>												
<b>TOTAL FEES ENCLOSED =</b>				\$	<b>1020.00</b>												
				Amount to be:													
				refunded	\$												
				Charged	\$												
a. <input checked="" type="checkbox"/> A check in the amount of \$1020.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input checked="" type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.																	
<b>NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>																	
<b>SEND ALL CORRESPONDENCE TO:</b>  NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 <sup>th</sup> Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 MJW:lks																	
 SIGNATURE																	
<b>Mary J. Wilson</b> NAME																	
<b>32,955</b> REGISTRATION NUMBER																	
March 21, 2002 Date																	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SCHNEIDER et al

Atty. Ref.: 620-190

Nat'l Phase Int'l Appln. No. PCT/GB00/03601

Group:

Int'l Filing Date: 20 September 2002

Examiner:

For: USE OF REPLICATION-DEFICIENT ADENOVIRAL VECTOR TO BOOST CD8+T  
CELL IMMUNE RESPONSE TO ANTIGEN

\* \* \* \* \*

March 21, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Please preliminarily amend the above-identified application  
as follows:

IN THE CLAIMS

Please cancel claims 1-8 without prejudice.

Please substitute the following amended claims for  
corresponding claims previously presented. A copy of the  
amended claims showing current revisions is attached.

SCHNEIDER, et al

Nat'l Phase Int'l Appln. No. PCT/GB00/03601

14. (Amended) A method according to claim 9 further comprising administration of another, different boosting composition comprising said antigen or epitope.

15. (Amended) A method according to claim 9 wherein the boosting composition is administered intradermally.

16. (Amended) A method according to claim 9 wherein the boosting composition is administered intramuscularly.

**REMARKS**

The above amendments have been made to place the application in a more traditional format.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: Mary J. Wilson

Mary J. Wilson  
Reg. No. 32,955

MJW:lks  
1100 North Glebe Road, 8th  
Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADEIN THE CLAIMS

14. (Amended) A method according to [any one of claims 9 to 13] claim 9 further comprising administration of another, different boosting composition comprising said antigen or epitope.

15. (Amended) A method according to [any one of claims 9 to 14] claim 9 wherein the boosting composition is administered intradermally.

16. (Amended) A method according to [any one of claims 9 to 14] claim 9 wherein the boosting composition is administered intramuscularly.

WO 01/21201

1

USE OF REPLICATION-DEFICIENT ADENOVIRAL VECTOR  
TO BOOST CD8+ T CELL IMMUNE RESPONSE TO ANTIGEN

The present invention relates to generation of a CD8+ T cell  
5 immune response against an antigen. More particularly, the  
present invention relates to "prime and boost" immunisation  
regimes in which the immune response induced by administration  
of a priming composition is boosted by administration of a  
boosting composition. The present invention is based on the  
10 inventors' experimental demonstration that effective boosting  
can be achieved using replication-defective adenovirus vectors,  
following priming with any of a variety of different types of  
priming compositions.

15 A major protective component of the immune response against a  
number of pathogens is mediated by T lymphocytes of the CD8+  
type, also known as cytotoxic T lymphocytes (CTL). An  
important function of CD8+ cells is secretion of gamma  
interferon (IFN $\gamma$ ), and this provides a measure of CD8+ T cell  
20 immune response.

CD8+ T cell response is important in protection against a  
number of parasites, including protozoan parasites such as  
*Toxoplasma* and *Trypanosoma*, *Plasmodium falciparum* (and in mice  
25 *P. berghei*), viruses such as HIV, herpes simplex, herpes  
zoster, HBV, HCV influenza, EBV, measles, dengue and HTLV-1,

bacteria such as *Mycobacterium tuberculosis* and *Listeria* sp, and various cancers, such as melanoma and renal carcinoma.

Infection of mice with *P. berghei* provides a good model for *P.*

- 5 *falciparum* malaria in humans, chosen by the inventors for exemplification of the ability of the present invention to provide strong CD8+ T cell immune responses against antigen. Malaria is a major health problem in the world and significant efforts have been directed in finding effective immune  
10 compositions for vaccination.

- In order to protect against the pre-erythrocytic stage of *Plasmodium falciparum* malaria, an immunogenic composition must induce a strong CD8+ T cell response. In general, live  
15 attenuated vaccines capable of producing a short-lived infection that is harmless in a healthy individual are effective at inducing T cell responses. Irradiated *Plasmodium* sporozoites, which can infect hepatocytes but do not progress to a blood-stage infection have been shown to protect both mice  
20 and men against malaria by inducing T cell responses against pre-erythrocytic antigens [Nardin and Nussenzweig (1993) Annu. Rev. Immunol. 11: 687-727]. However in man this requires multiple immunisations over a long period of time, and whilst these experimental immunisations have provided valuable  
25 information, this approach is not useful for development of a vaccine.

Recombinant protein subunit vaccines elicit humoral responses, but poor CD8+ T cell responses [Schirmbeck et al., (1995) Vaccine 13(9): 857-865]. DNA vaccines have been shown to elicit both humoral and cellular responses against the *P. yoelii* CS protein [Sedegah et al., (1994) Proc. Natl. Acad. Sci. USA 91(21): 9866-70]. However, mice immunised with a DNA vaccine expressing the *P. berghei* CS gene had only a weak CD8+ T cell response to the protective CD8+ T cell epitope pb9 [Romero et al., (1989) Nature 341(6240): 323-6] and were not protected against challenge with infectious sporozoites even after repeated immunisations [Schneider et al., (1998) Nat. Med. 4(4): 397-402]. Ty virus-like particles, consisting of a recombinant protein assembled into a 30nm particle, induce stronger CD8+ T cell responses, but do not protect against infection [Gilbert et al., (1997) Nat. Biotechnol. 15(12): 1280-4].

Recombinant viruses can also be used as vaccines. Modified Vaccinia virus Ankara (MVA) does not replicate in human cells and is a very safe virus to use as a vaccine [Mayr et al., (1978) Zentralbl. Bakteriол. 167(5-6): 375-90; Sutter and Moss (1992) Proc. Natl. Acad. Sci. 89(22): 10847-51; Sutter et al., (1994) Vaccine 12(11): 1032-40]. Recombinant MVA expressing *P. berghei* CS has also been tested in mice, resulting in similar levels of peptide-specific lysis in a cytotoxicity assay as mice immunised with Ty VLPs [Gilbert et al., (1999) Biol. Chem.



WO 01/21201

PCT/GB00/03601

4

380(3): 299-303]. Again, these mice were not protected against infectious challenge. However, despite the fact that neither DNA vaccines, Ty VLPs or MVA used alone can protect against malaria infection, using either DNA or Ty VLPs to prime a T cell response and MVA to boost it results in greatly increased numbers of IFN- $\gamma$  secreting CD8+ T cells, and complete protection against infection when the MVA is administered intravenously [Schneider et al., (1998) Nat. Med. 4(4): 397-402, WO98/56919].

10

The present invention employs replication-deficient adenovirus which, as the experiments described below show, has been found to be an effective means for providing a boost to a CD8+ T cell immune response primed to antigen using any of a variety of different priming compositions.

15

Replication-deficient adenovirus derived from human serotype 5 has been developed as a live viral vector by Graham and colleagues [Graham and Prevec (1995) Mol. Biotechnol. 3(3): 207-20; Bett et al., (1994) Proc. Natl. Acad. Sci. USA 91(19): 8802-6]. Adenoviruses are non-enveloped viruses containing a linear double stranded DNA genome of around 3600 bp. Recombinant viruses can be constructed by *in vitro* recombination between an adenovirus genome plasmid and a shuttle vector containing the gene of interest together with a strong eukaryotic promoter, in a permissive cell line which

25

allows viral replication. High viral titres can be obtained from the permissive cell line, but the resulting viruses, although capable of infecting a wide range of cell types, do not replicate in any cells other than the permissive line, and are therefore a safe antigen delivery system. Recombinant adenoviruses have been shown to elicit protective immune responses against a number of antigens including tick-borne encephalitis virus NS1 protein [Jacobs et al., (1992) J. Virol. 66(4): 2086-95] and measles virus nucleoprotein [Fooks et al., (1995) Virology 210(2): 456-65]. Further, a single dose of recombinant adenovirus resulted in a 93% decrease in the level of hepatic parasite rRNA of *P. yoelii* in mice, and 40% protection, which was shown to be CD8+ T cell-mediated [Rodrigues et al., (1997) J. Immunol. 158(3): 1268-74].

Remarkably, the experimental work described below demonstrates that use of embodiments of the present invention allows for recombinant replication-defective adenovirus expressing an antigen (specifically exemplified with the CS gene from *Plasmodium berghei*) to boost a CD8+ T cell immune response primed by a DNA vaccine, Ty-VLPs or recombinant modified Vaccinia virus Ankara (MVA). The replication-defective adenovirus was found to induce a CD8+ T cell response after intradermal or intramuscular immunisation. In prime/boost vaccination regimes the replication-defective adenovirus was also able to prime a response that could be boosted by MVA.

Mice immunised with the replication-defective adenovirus and boosted with the MVA were completely protected against *P. berghei* sporozoite challenge. Both recombinant replication-deficient adenovirus and recombinant MVA are vaccines that are safe for use in humans. Advantageously, the inventors found that a vaccination regime used intradermal immunisation for both prime and boost can be employed, constituting a general immunisation regime suitable for inducing CD8+ T cells, e.g. in humans.

10

The present invention in various aspects and embodiments employs a replication-deficient adenovirus vector encoding an antigen for boosting a CD8+ T cell immune response to the antigen primed by previous administration of the antigen or nucleic acid encoding the antigen.

15

A general aspect of the present invention provides for the use of a replication-deficient adenoviral vector for boosting a CD8+ T cell immune response to an antigen.

20

One aspect of the present invention provides a method of boosting a CD8+ T cell immune response to an antigen in an individual, the method including provision in the individual of a replication-deficient adenoviral vector including nucleic acid encoding the antigen operably linked to regulatory sequences for production of antigen in the individual by

25

WO 01/21201

PCT/GB00/03601

7

expression from the nucleic acid, whereby a CD8+ T cell immune response to the antigen previously primed in the individual is boosted.

- 5 An immune response to an antigen may be primed by immunisation, by infection with an infectious agent, or by development of a tumour or malignancy.

A further aspect of the invention provides a method of inducing  
10 a CD8+ T cell immune response to an antigen in an individual, the method comprising administering to the individual a priming composition comprising the antigen or nucleic acid encoding the antigen and then administering a boosting composition which  
15 comprises a replication-deficient adenoviral vector including nucleic acid encoding the antigen operably linked to regulatory sequences for production of antigen in the individual by expression from the nucleic acid.

A further aspect provides for use of a replication-deficient  
20 adenoviral vector, as disclosed, in the manufacture of a medicament for administration to a mammal to boost a CD8+ T cell immune response to an antigen. Such a medicament is generally for administration following prior administration of a priming composition comprising the antigen.

25

The priming composition may comprise any viral vector, although

- generally other than adenoviral, such as a vaccinia virus vector such as a replication-deficient strain such as modified virus ankara (MVA) (Mayr et al., (1978) Zentralbl. Bakteriол. 167(5-6): 375-90; Sutter and Moss (1992) Proc. Natl. Acad. Sci. 89(22): 10847-51; Sutter et al., (1994) Vaccine 12(11): 1032-40) or NYVAC (Tartaglia et al., Virology (1992) 118(1): 217-32), an avipox vector such as fowlpox or canarypox, e.g. the strain known as ALVAC (Kanapox, Paoletti et al., Dev Biol Stand (1994) 82: 65-9), or a herpes virus vector. The priming composition may comprise a recombinant bacterial vector, such as recombinant BCG or *Salmonella*. A priming composition comprising a recombinant fowlpox virus is among preferred embodiments for use in the present invention.
- 15 The priming composition may comprise DNA encoding the antigen, such DNA preferably being in the form of a circular plasmid that is not capable of replicating in mammalian cells. Any selectable marker should not be resistance to an antibiotic used clinically, so for example Kanamycin resistance is preferred to Ampicillin resistance. Antigen expression should be driven by a promoter which is active in mammalian cells, for instance the cytomegalovirus immediate early (CMV IE) promoter.

- The priming composition may be a recombinant Ty-VLP. These are protein particles consisting of a single protein species from the Ty1 retrotransposon of *S. cerevisiae* which spontaneously

assembles into particles. Recombinant Ty-VLP's may be produced by fusing the coding sequence of the required epitope or antigen to the 3' end of the coding sequence for the TyA protein, and transforming *S. cerevisiae* with a vector including  
5 the coding sequence for expression of the fusion protein which then assembles into particles in the yeast cytoplasm from where they may be purified. The particulate nature of the Ty-VLP's allows them to be taken up by antigen presenting cells and prime a CD8+ T cell response to epitopes contained within them.

10

Other suitable priming compositions include lipid-tailed peptides, fusion proteins, adjuvant compositions and so on.

In particular embodiments of the various aspects of the present  
15 invention, administration of a priming composition is followed by boosting with first and second boosting compositions, the first and second boosting compositions being different from one another, e.g. as exemplified below. Still further boosting compositions may be employed without departing from the present  
20 invention. In one embodiment, a triple immunisation regime employs DNA, then adenovirus as a first boosting composition, and then MVA as a second boosting composition, optionally followed by a further (third) boosting composition or subsequent boosting administration of one or other or both of  
25 the same or different vectors. Another option is DNA then MVA then Ad, optionally followed by subsequent boosting

WO 01/21201

PCT/GB00/03601

10

administration of one or other or both of the same or different vectors.

The antigen to be included in respective priming and boosting  
 5 compositions (however many boosting compositions are employed) need not be identical, but should share at least one CD8+ T cell epitope. The antigen may correspond to a complete antigen in a target pathogen or cell, or a fragment thereof. Peptide epitopes or artificial strings of epitopes may be employed,  
 10 more efficiently cutting out unnecessary protein sequence in the antigen and encoding sequence in the vector or vectors. One or more additional epitopes may be included, for instance epitopes which are recognised by T helper cells, especially epitopes recognised in individuals of different HLA types (such  
 15 as tetanus epitopes).

Within the replication-deficient adenoviral vector, regulatory sequences for expression of the encoded antigen will include a promoter. By "promoter" is meant a sequence of nucleotides  
 20 from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA). "Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter.  
 25 DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter. Other regulatory

sequences including terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences may be included as appropriate, in accordance with the knowledge and practice of the ordinary person skilled in the

5 art: see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction  
10 of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons, 1994.

15 Suitable promoters for use in aspects and embodiments of the present invention include the cytomegalovirus immediate early (CMV IE) promoter, with or without intron A, and any other promoter that is active in mammalian cells.

20 Either or both of the priming and boosting compositions may include an adjuvant, such as granulocyte macrophage-colony stimulating factor (GM-CSF) or encoding nucleic acid therefor.

Administration of the boosting composition is generally about  
25 10 days to 4 weeks after administration of the priming composition, preferably about 2-3 weeks.



Preferably, administration of priming composition, boosting composition, or both priming and boosting compositions, is intradermal or intramuscular immunisation

- 5 Intradermal administration of adenovirus and MVA vaccines may be achieved by using a needle to inject a suspension of the virus. An alternative is the use of a needleless injection device to administer a virus suspension (using e.g. Biojector™) or a freeze-dried powder containing the vaccine (e.g. in
- 10 accordance with techniques and products of Powderject), providing for manufacturing individually prepared doses that do not need cold storage. This would be a great advantage for a vaccine that is needed in rural areas of Africa.
- 15 Adenovirus and MVA are both viruses with an excellent safety record in human immunisations. The generation of recombinant viruses can be accomplished simply, and they can be manufactured reproducibly in large quantities. Intradermal administration of recombinant replication-deficient adenovirus
- 20 followed by recombinant MVA is therefore highly suitable for prophylactic or therapeutic vaccination of humans against diseases which can be controlled by a CD8+ T cell response.

The individual may have a disease or disorder such that

- 25 delivery of the antigen and generation of a CD8+ T cell immune response to the antigen is of benefit or has a therapeutically

beneficial effect.

Most likely, administration will have prophylactic aim to generate an immune response against a pathogen or disease before infection or development of symptoms.

Diseases and disorders that may be treated or prevented in accordance with the present invention include any noted already above and others in which a CD8+ T cell immune response may play a protective or therapeutic role.

Components to be administered in accordance with the present invention may be formulated in pharmaceutical compositions. These compositions may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

As noted, administration is preferably intradermal, subcutaneous or intramuscular.

Liquid pharmaceutical compositions generally include a liquid

WO 01/21201

PCT/GB00/03601

14

carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

A slow-release formulation may be employed.

Following production of replication-deficient adenoviral particles and optional formulation of such particles into compositions, the particles may be administered to an individual, particularly human or other primate. Administration may be to another mammal, e.g. rodent such as mouse, rat or hamster, guinea pig, rabbit, sheep, goat, pig, horse, cow, donkey, dog or cat.

Administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual  
5 amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, or in a veterinary  
10 context a veterinarian, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in  
15 Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

In one preferred regimen, DNA is administered (preferably intramuscularly) at a dose of 0.5 mg/injection, followed by  
20 adenovirus (preferably intramuscularly or intradermally) at a dose of  $5 \times 10^7$  -  $5 \times 10^8$  virus particles/injection.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially  
25 dependent upon the condition to be treated.

Delivery to a non-human mammal need not be for a therapeutic purpose, but may be for use in an experimental context, for instance in investigation of mechanisms of immune responses to an antigen of interest, e.g. protection against cancers, malaria, other pathogens and so on.

Further aspects and embodiments of the present invention will be apparent to those of ordinary skill in the art, in view of the above disclosure and following experimental exemplification, included by way of illustration and not limitation, and with reference to the attached figures, wherein:

Figure 1 shows results of experiments demonstrating peptide-specific IFN- $\gamma$  secreting T cells primed by a single immunisation of Ad-PbCS. Groups of three mice were immunised via the routes shown using  $10^7$  pfu. Elispot assays to detect IFN- $\gamma$  secreting pb9-specific T cells were performed in duplicate on splenocytes after two weeks. The graph shows spot forming cells (SFC) per million splenocytes for each route of administration.

Figure 2 shows results of prime/boost immunisations. Groups of three mice were immunised on day 0 with the first vaccine shown (D = pSG2.PbCS, A = Ad-PbCS, M = MVA-PbCS), and day 14 with the second vaccine. DNA was injected i.m., adenovirus and MVA i.d.

Elispots were performed on splenocytes isolated on day 28. The graph shows SFC per million splenocytes for each prime/bosst immunisation regime.

- 5 Figure 3 shows results of triple combination immunisations, and comparison with double combination immunisations. Groups of three mice were immunised at 10 day intervals with the vaccines shown (D = pSG2.PbCS, A = Ad-PbCS, M = MVA-PbCS), with the first vaccine of the double combinations given on the same day
- 10 as the second vaccine of the triple combinations. Elispot assays were performed in duplicate on splenocytes 10 days after the last immunisation. The graph shows SFC per million splenocytes for each immunisation regime.

## 15 EXPERIMENTAL EXEMPLIFICATION

- The inventors constructed a recombinant replication deficient adenovirus expressing the CS gene of *P. berghei*, (Ad-PbCS) and tested the capabilities of this virus to induce CD8+ T cell
- 20 responses in mice either alone or in combination with other types of vaccines.

- When used as a single immunisation high levels of antigen-specific CD8+ T cells were generated. Adenovirus priming
- 25 followed by MVA boosting resulted in complete protection.



confirmed by immunofluoresence. Large quantities of virus were prepared from infected 293 cells and purified by extraction with Arklone [Graham and Prevec (1995) Mol. Biotechnol. 3(3): 207-20] prior to immunisation.

5

#### *Ty VLPs*

Recombinant Ty VLPs expressing the pb9 epitope from *P. berghei* CS, SYIPSAEKI, were prepared as described in [Gilbert et al., (1997) Nat. Biotechnol. 15(12): 1280-4] and suspended in PBS.

10

#### *Recombinant MVA*

MVA expressing *P. berghei* CS was prepared by *in vitro* recombination between a shuttle vector containing the CS gene driven by the vaccinia P7.5 promoter and MVA virus in primary  
15 chick embryo fibroblasts [Sutter et al., (1994) Vaccine 12(11): 1032-40]. The recombinant, which also expresses *E. coli*  $\beta$ -galactosidase, was repeatedly plaque purified and expression of the recombinant gene was confirmed by immunofluoresence. Virus for immunisation was purified by ultracentrifugation through a  
20 sucrose cushion and suspended in endotoxin-free PBS.

#### *Immunisations*

Female BALB/c mice 4-6 weeks old were immunised under anaesthesia as described for individual experiments.  
25 Intramuscular DNA immunisations used 50  $\mu$ g DNA in each musculus tibialis. MVA and adenovirus ( $10^6$  and  $10^7$  pfu per dose



respectively) were injected intradermally into the ear pinnae. Ty VLPs (100 µg per dose) were injected intradermally in the footpad or intravenously into the lateral tail vein.

#### 5 *ELISPOT assays*

- The number of IFN-γ secreting, pb9-specific T cells in fresh splenocyte preparations was determined as described previously [Schneider et al., (1998) Nat. Med. 4(4): 397-402] by coating 96-well nitrocellulose plates with anti-mouse IFN-γ antibody
- 10 (clone R4 from ETCC), washing with PBS and subsequent blocking with complete medium containing 10% FCS. Splenocytes from immunised mice were resuspended at  $1-2 \times 10^7$  cells/ml and placed in duplicates into the coated wells, and serially diluted. The H2-K<sup>d</sup> -restricted peptide pb9 (SYIPSAEKI)
- 15 (Romero) was added to test wells and an irrelevant peptide to control wells. After overnight incubation the wells were washed and a second, biotinylated anti-IFN-γ antibody (Pharmingen clone) added to the wells. The wells were washed again and streptavidin-alkaline phosphatase was added. After
- 20 further washing, spots were developed by adding an alkaline phosphatase substrate. The reaction was stopped by washing the wells and spots were counted under a stereomicroscope.

#### *P. berghei challenge*

- 25 Sporozoites of *P. berghei* (ANKA strain clone 1) were obtained

from laboratory reared female *Anopheles stephensi* mosquitoes maintained at 18 °C for 20-25 days after feeding on infected mice. Salivary glands from the mosquitoes were collected by dissection and placed in a tissue homogeniser with RPMI 1640 (Sigma) to release the sporozoites, which were then counted using a haemocytometer. Mice were challenged by injection of 2000 sporozoites into the tail vein. Infection was determined by the presence of ring forms in Giemsa stained blood smears taken 7 and 9 days post challenge. If blood-stage parasitaemia was observed at two time points the mice were sacrificed. Surviving animals were observed for at least a further three weeks for the development of malaria symptoms.

## RESULTS

15

### *Immunogenicity of single adenovirus immunisations using different routes of administration*

Initially the effect of the route of administration on the ability of Ad-PbCS to induce pb9-specific IFN- $\gamma$  secreting T cells was tested.

20

Rodrigues *et al.* (1997) J. Immunol. 158(3): 1268-74 had found high levels of malaria-specific CD8+ T cells were induced after i.m. and s.c. immunisation, but not i.v., i.p. or i.n. The inventors did not test i.v. or i.p. as these are not suitable routes for a prophylactic vaccine to be used in humans, but

25

included i.d. and "gene paint" groups - simple administration of recombinant adenovirus onto the skin (known as gene painting), previously shown to be able to induce an immune response against the antigen expressed by the virus [Tang et al., (1997) Nature 388(6644): 729-30].

Groups of mice received a single immunisation of  $10^7$  pfu Ad-PbCS and splenocytes were tested for peptide-specific IFN- $\gamma$  secreting T cells after 14 days.

The numbers of peptide-specific IFN- $\gamma$  secreting T cells (Figure 1) detected after i.m. or i.d. immunisation were somewhat higher than those detected after a single immunisation with i.m. DNA, and slightly lower than those detected after i.m. MVA [Gilbert et al., (1999) Biol. Chem. 380(3): 299-303].

Intranasal or s.c. immunisation produced very low numbers of peptide-specific IFN- $\gamma$  secreting T cells, and none could be detected in the "gene-paint" group. Intradermal immunisation was used for all subsequent experiments.

#### *Immunogenicity of different prime/boost immunisations*

Figure 2 shows the numbers of peptide-specific IFN- $\gamma$  secreting T cells detected in the spleens of immunised mice receiving a priming immunisation on day 0 and a boosting immunisation on day 14.

Using the same vaccine to prime and boost resulted in an increase in specific CD8+ T cells, but a far greater increase was seen after heterologous boosting. DNA does not boost an existing response. However the combination of adenovirus

5 priming and MVA boosting resulted in extremely high numbers of peptide specific CD8+ T cells. In addition to being able to prime a response that could be boosted to such high levels, Ad-PbCS was able to boost a response that had been primed by DNA or MVA.

10

*Immunogenicity of triple combination immunisations*

Heterologous priming and boosting is clearly much more effective than using the same vaccine repeatedly. Three different vaccines were employed sequentially. DNA vaccines do  
15 not boost, so two combinations were possible, and employed: DNA/Ad/MVA and DNA/MVA/Ad. Groups of mice were immunised at 10 day intervals and splenocytes were tested 10 days after the final immunisation.

20 As in the previous experiment high numbers of peptide-specific IFN- $\gamma$  secreting T cells were detected after DNA/MVA, Ad/MVA, MVA/Ad and DNA/Ad immunisations (Figure 3). However these numbers were not increased to the same extent (three to ten-fold) when a third heterologous boosting immunisation was  
25 given.

*Protection against infectious challenge*

Several of the prime/boost combinations employing adenovirus as either a priming or boosting agent had resulted in high numbers of peptide-specific IFN- $\gamma$  secreting T cells that would be

5 expected to protect mice against challenge with *P. berghei* sporozoites. Therefore groups of eight to eleven mice were immunised with a number of different heterologous prime/boost combinations and challenged with 2000 infectious *P. berghei* sporozoites two weeks after the boosting immunisation. The  
10 results are shown in Table 1.

Intradermal administration of adenovirus followed by i.d. MVA completely protected the immunised mice. In earlier *P. berghei* challenge experiments it was found that i.m. DNA followed by  
15 i.d. MVA gave a high level of protection, but that complete protection was only achieved when the MVA was administered intravenously [Schneider et al., (1998) Nat. Med. 4(4): 397-402]. However using adenovirus priming and MVA boosting, both  
20 vaccines could be given intradermally with no loss of protection. MVA priming and adenovirus boosting also resulted in a high level of protection, whereas two subsequent adenovirus immunisations did not. Adenovirus also boosted  
25 responses primed by DNA or Ty-VLPs resulting in levels of protection comparable to that obtained by DNA priming and i.d. MVA boosting.

TABLE 1

Protection of mice immunised with different heterologous prime/boost combinations. DNA was given intramuscularly (50 µg dose). MVA (10<sup>6</sup> ffu dose) adenovirus (10<sup>7</sup> pfu dose) and Ty VLPs (100 µg dose) were administered intradermally unless otherwise stated. The priming immunisation was given on day 0, the boosting immunisation on day 14, and the challenge carried out on day 28.

10

	Prime	Boost	No.	No.	%
			infected	Challenged	Protection
15	DNA	MVA	5	10	50
	Ad	MVA	0	10	100
	MVA	Ad	2	10	80
	Ad	Ad	7	8	13
	DNA	Ad	5	11	55
	MVA	MVA	5	8	38
20	Ty (i.v.)	Ad	7	10	30
	Ty (i.v.)	MVA (i.v.)	1	11	91
	Ty	Ad	4	10	60
	naïve		8	10	20

**ART 34 AMEND**CLAIMS

1. Use of a replication-deficient adenoviral vector encoding an antigen or a CD8+ T cell epitope of said antigen, in the manufacture of a medicament for treating an individual in which a CD8+ T cell immune response to the antigen is of therapeutic or prophylactic benefit, wherein the medicament is for administration to such an individual to boost in the individual a CD8+ T cell immune response to the antigen following prior administration of a non-adenoviral priming composition comprising said antigen or epitope or nucleic acid encoding said antigen or epitope.
2. Use according to claim 1 wherein the priming composition comprises DNA encoding said antigen or epitope.
3. Use according to claim 1 wherein the priming composition comprises recombinant Ty-VLP
4. Use according to claim 1 wherein the priming composition comprises Modified Virus Ankara (MVA).
5. Use according to any one of claims 1 to 4 wherein the medicament is a boosting composition for administration prior to administration of another, different boosting composition comprising said antigen or epitope.

6. Use according to any one of claims 1 to 4 wherein the medicament is a boosting composition for administration following administration of another, different boosting comprising said antigen or epitope.

7. Use according to any one of claims 1 to 6 wherein the medicament is for intradermal administration.

8. Use according to any one of claims 1 to 6 wherein the medicament is for intramuscular administration.

9. A method of boosting a CD8+ T cell immune response to an antigen in an individual, the method including provision in the individual of a replication-deficient adenoviral vector including nucleic acid encoding the antigen or a CD8+ T cell epitope of said antigen operably linked to regulatory sequences for production of said antigen or epitope in the individual by expression from the nucleic acid, whereby a CD8+ T cell immune response to the antigen previously primed with a non-adenoviral vector in the individual is boosted.

10. A method of inducing a CD8+ T cell immune response to an antigen in an individual, the method comprising administering to the individual a priming composition comprising the antigen or a CD8+ T cell epitope of said antigen or nucleic acid encoding said antigen or epitope and then administering a



boosting composition which comprises a replication-deficient adenoviral vector including nucleic acid encoding said antigen or epitope operably linked to regulatory sequences for production of said antigen or epitope in the individual by

5 expression from the nucleic acid.

11. A method according to claim 10 wherein the priming composition comprises DNA encoding said antigen or epitope.

10 12. A method according to claim 10 wherein the priming composition comprises recombinant Ty-VLP

13. A method according to claim 10 wherein the priming composition comprises Modified Virus Ankara (MVA).

15

14. A method according to any one of claims 9 to 13 further comprising administration of another, different boosting composition comprising said antigen or epitope.

20 15. A method according to any one of claims 9 to 14 wherein the boosting composition is administered intradermally.

16. A method according to any one of claims 9 to 14 wherein the boosting composition is administered intramuscularly.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
WO 01/21201 A3


- (51) International Patent Classification<sup>7</sup>: C12N 15/30, A61K 39/00, 39/015
- (52) International Application Number: PCT/GB00/03601
- (53) International Filing Date: 20 September 2000 (20.09.2000)
- (54) Filing Language: English
- (55) Publication Language: English
- (56) Priority Data: 9922361.2 21 September 1999 (21.09.1999) GB
- (57) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; Ewert House, Ewert Place, Summertown, Oxford OX2 7BZ (GB).
- (58) Inventors; and  
(59) Inventors/Applicants (for US only): SCHNEIDER, Jørg [DE/GB]; 11 Malford Road, Barton, Oxford OX3 8BT (GB). GILBERT, Sarah, Catherine [GB/GB]; 65 Dene Road, Headington, Oxford OX3 7EQ (GB). HANNAN, Carolyn, Mary [AU/GB]; 42 Percy Street, Oxford OX4 3AA (GB). HILL, Adrian, Vivian, Sinton [GB/GB]; 2 St Andrew's Road, Oxford OX3 9DL (GB).
- (60) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (61) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (62) Date of publication of the international search report: 18 October 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF REPLICATION-DEFICIENT ADENOVIRAL VECTOR TO BOOST CD8+ T CELL IMMUNE RESPONSE TO ANTIGEN

(57) Abstract: Use of a replication-deficient adenoviral vector encoding an antigen or a CD8+ T cell epitope of the antigen to boost in the individual a CD8+ T cell immune response to the antigen following prior administration of a priming composition. The priming composition comprises the antigen or epitope or nucleic acid encoding the antigen or epitope, and may be DNA, Ty-LVP<sup>®</sup> S or Modified Virus Ankara (MVA). Administration may be intradermal or intramuscular.

WO 01/21201 A3

Figure 1



2/3

Figure 2





Figure 3



**RULE 63 (37 C.F.R. 1.63)**  
**INVENTORS DECLARATION FOR PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**USE OF REPLICATION-DEFICIENT ADENOVIRAL VECTOR TO BOOST CD8+T CELL IMMUNE RESPONSE TO ANTIGEN**

the specification of which (check applicable box(es)):

☐ is attached hereto  
☐ was filed on \_\_\_\_\_ as U.S. Application Serial No. \_\_\_\_\_ (Att'y Dkt. No. 620-190)  
☒ was filed as PCT international application No. \_\_\_\_\_ PCT/GB00/03601 on 20 September 2000  
 and (if applicable to U.S. or PCT application) was amended on 05 November 2001

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number 9922361.2	Country Great Britain	Day/Month/Year Filed 21 September 1999
---------------------------------	--------------------------	---

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number	Date/Month/Year Filed
--------------------	-----------------------

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below:

Prior U.S./PCT Application(s):

Application Serial No. PCT/GB00/03601	Day/Month/Year Filed 20 September 2000	Status: patented pending, abandoned
--	---	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) herof, I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8<sup>th</sup> Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25840; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32105; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffery H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34778; Dedeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Prestia, 19828; Joseph S. Prestia, 35524; Joseph A. Rhoos, 37515; Raymond Y. Mah, 41426; Chris Comuntzils, 33107; Gary T. Tanigawa, 43180. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature: [Signature] Date: 3 MAY 2002  
 Inventor: JOHN SCHNEIDER (first) MI (last) German (citizenship)  
 Residence: (city) Oxford (state/country) United Kingdom  
 Mailing Address: 11 Malford Road, Barton, Oxford, United Kingdom  
 (Zip Code) OX3 8BT

2. Inventor's Signature: [Signature] Date: 1 May 2002  
 Inventor: Sarah GILBERT (first) MI (last) British (citizenship)  
 Residence: (city) Oxford (state/country) United Kingdom  
 Mailing Address: 65 Dene Road, Headington, Oxford, United Kingdom  
 (Zip Code) OX3 7EQ  
7 Manor Farm Road, Horspath  
OX3 3 1SO

☒ See attached sheet(s) for additional inventor(s) information!!

**RULE 63 (37 C.F.R. 1.63)  
INVENTORS DECLARATION FOR PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**USE OF REPLICATION-DEFICIENT ADENOVIRAL VECTOR TO BOOST CD8+ T CELL IMMUNE RESPONSE TO ANTIGEN**

the specification of which (check applicable box(es)):

☐ is attached hereto  
☒ was filed on \_\_\_\_\_ as U.S. Application Serial No. \_\_\_\_\_ (Atty Dkt. No. 620-190)  
☒ was filed as PCT International application No. PCT/GB00/03601 on 20 September 2000  
 and (if applicable to U.S. or PCT application) was amended on 05 November 2001

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number  
9922361.2

Country  
Great Britain

Day/Month/Year Filed  
21 September 1999

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number

Date/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below:

Prior U.S./PCT Application(s):

Application Serial No.  
PCT/GB00/03601

Day/Month/Year Filed  
20 September 2000

Status: patented  
pending, abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8<sup>th</sup> Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoads, 37515; Raymond Y. Mah, 41426; Chris Comuntzis, 31097; Gary T. Tanigawa, 43180. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

3. Inventor's Signature: C.M. Hannan, C.M. Hannan Date: 19 April 2002  
 3-00 Inventor: Carolyn M HANNAN Australian  
 (first) (last) (citizenship)  
 Residence: (city) Oxford SCOPE (UK) (state/country) United Kingdom AUSTRALIA (CH)  
 Mailing Address: 42 Percy Street, Oxford, United Kingdom 41 TONARRI ST (CH)  
 (Zip Code) OX4 3AA SCOPE, NSW, 2337, AUSTRALIA (CBD) AuX

4. Inventor's Signature: [Signature] Date: 26/4/2002  
 4-00 Inventor: Adrian V.S. HILL British/Irish  
 (first) (last) (citizenship)  
 Residence: (city) Oxford (state/country) United Kingdom  
 Mailing Address: 20 Saint Andrew's Road, Oxford, United Kingdom  
 (Zip Code) OX3 9DL G-BX

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.